Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Richardson Labs' Arthred-G osteoarthritis claims subject of FDA "courtesy letter".

This article was originally published in The Tan Sheet

Executive Summary

RICHARDSON LABS ARTHRED-G CARTILAGE CLAIM DRAWS "COURTESY LETTER" from FDA's Center for Food Safety & Applied Nutrition Office of Special Nutritionals. In the Aug. 6 advisory letter, FDA cites one of the company's registered "structure/function" claims for Arthred-G -- "provides proactive nutritional support for cartilage degeneration" -- which "suggests that [the product] is intended to treat, mitigate, prevent, or cure a disease, namely osteoarthritis". The claim causes the product to be classified as a drug under the FD&C Act, FDA asserts. Richardson Labs has since changed the claim to "provides nutritional support for cartilage regeneration.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087865

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel